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Background and Terms of Reference
Regulation (EC) No 1831/20031 establishes the rules governing the Community authorisation of
additives for use in animal nutrition. Moreover, Regulation (EC) No 429/20082 provides detailed rules
for the implementation of Regulation (EC) No 1831/2003 as regards the preparation and the
presentation of applications and the assessment and the authorisation of feed additives.
The Panel on Additives and Products or Substances used in Animal Feed (FEEDAP Panel) has
adopted a series of guidance documents which aim at complementing Regulation (EC) No 429/2008 to
support applicants in the preparation and submission of technical dossiers for the authorisation of
additives for use in animal nutrition according to Regulation (EC) No 1831/2003.
The European Food Safety Authority (EFSA) asked its FEEDAP Panel to:
1) identify from the current guidance documents, those that need to be updated, taking into
consideration the most recent scientiﬁc developments and the experience gained in the
assessment of feed additives;
2) update the guidance documents in need of revision accordingly; this activity can be
conducted in different rounds of activities on the basis of the priorities identiﬁed and on the
feasibility of the revision according the resources available;
3) taking into account the sensitivity and the relevance of some of the guidance documents
under revision and the entity of the revision itself (e.g. substantial or not), consider initiatives
like preparatory info-sessions or public consultations of the draft guidance documents. The
relevant comments received in either step will have to be considered and addressed if
appropriate in the ﬁnal version of the guidance documents.
The ﬁrst of the terms of reference was addressed by a statement of the EFSA FEEDAP
Panel (2016), in which it was identiﬁed the need to update most of the guidance documents that it
produced and set priorities for this update.
This output addresses the second and third terms of reference with regard to the update of the
guidance documents dealing with the assessment of the safety of feed additives for the target species.
This guidance document underwent a public consultation (EFSA, 2017).
Scope of the guidance
This guidance document is part of a series of documents intended to assist the applicant in the
preparation and the presentation of its application for authorisation of a feed additive, as foreseen in
Article 7.6 of Regulation (EC) No 1831/2003. This document does not substitute for the obligation of an
applicant to comply with the requirements of Regulation (EC) No 1831/2003 and its implementing rules.
Applicants should justify the omission from the dossier of any data or any deviations from the
requirements detailed in this guidance.
1. Introduction
Studies involving animals should respect the rules on animal welfare laid down by European Union
(EU) legislation, particularly those listed in Directive 63/2010/EU, and they should not be repeated if
available elsewhere.3 The use of methods reﬁning or replacing the tests using experimental animals or
reducing the number of animals used in these tests shall be encouraged. Such methods must provide
the same level of assurance as the methods they aim to replace.
For certain additives, safety for the target animals can be presumed without the need for speciﬁc
information. For all other additives, safety for the target animals can be assessed by extensive
literature searches for studies on target animals, toxicity data (either existing or new) from repeated
dose studies in laboratory animals or tolerance studies in target animals.
1 Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use in
animal nutrition. OJ L 268, 18.10.2003, p. 29.
2 Commission Regulation (EC) No 429/2008 of 25 April 2008 on detailed rules for the implementation of Regulation (EC) No
1831/2003 of the European Parliament and of the Council as regards the preparation and the presentation of applications and
the assessment and the authorisation of feed additives. OJ L 133, 22.5.2008, p. 1.
3 Without prejudice to Article 20 of Regulation (EC) No 1831/2003.
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2. Additives for which safety can be presumed without additional
studies
For the following additives, safety for the target animals can be presumed without the need for
additional studies:
• additives for which no exposure of the target animals to the active substance (or related
substances, including contaminants) will occur. Appropriate analytical data to determine that
the active substance (or related substances) is not detectable in feed at the time of feeding
should be provided.
• silage additives where it can be demonstrated that the active substance(s) and/or agent(s)
occur as normal constituents of silage and use of the additive does not substantially increase
their concentration compared to silage prepared without use of the additive (i.e. where there is
no substantial change in exposure).
• microorganisms satisfying the requirements of the qualiﬁed presumption of safety (QPS)
approach to safety assessment (EFSA, 2007; EFSA BIOHAZ Panel, 2017), or when its biology is
sufﬁciently well known to allow pathogenic/toxigenic strains to be excluded by direct testing,
provided that all other added components of the additive do not raise safety concerns.
• nutritional additives assessed and authorised following the provisions of Regulation (EC)
No 1831/2003.
• nutritional additives not already authorised:
– when the active substance is sufﬁciently puriﬁed. A product will be considered as
sufﬁciently puriﬁed if the unidentiﬁed fraction would not contribute to more than 1% (in
dry matter (DM)) when the inclusion rate does not exceed 1,000 mg additive/kg complete
feed. Higher inclusion rates would need a higher degree of purity (e.g. 10,000 mg
additive/kg feed would correspond to 0.1%).
– when the additive is produced by fermentation using a production organism that (i)
satisﬁes the requirements of the QPS approach to safety assessment or (ii) is a genetically
modiﬁed microorganism (GMM) for which the recipient strain is considered by EFSA to
qualify for the QPS approach to safety assessment and for which the molecular/genetic
characterisation does not give rise to concern.
3. Extensive literature search for studies with target animals
An extensive literature search may provide information on the safety of the feed additive under the
proposed conditions of use. The analysis of these data must establish that the active substance(s)/
agent(s) in literature studies is (are) identical to that under application or, if not, would still allow
conclusions on the additive under application to be made; for additives produced by fermentation,
identity includes the production strain. For additives consisting of a mixture, the extensive literature
search should cover all the components of the mixture. The concentration of the active substance/
agent in feed should preferably exceed or at least cover that proposed in the application. The target
species covered in the literature search should be relevant to the application. Application level,
replicates, duration, and zootechnical and clinical endpoints measured should allow a conclusion on the
absence of adverse effects. This may be achieved by the consideration of data from a number of
independent studies. The literature search should also cover all available toxicological endpoints
including genotoxicity.
Relevant information sources should be searched in a structured manner. The applicant should
make reasonable efforts to locate all sources of relevant information and provide reasons for the
selection of such sources. Bibliographic databases (including at least agricultural/aquacultural and
medical/veterinary databases) which record documents such as journals, reports, conference
proceedings and books should be searched. In addition, the search should consider sources other than
bibliographic databases, such as reference lists of full-text journal articles (e.g. reviews), websites of
conferences or organisations.
Applicants should follow the recommendations of the ‘Technical manual for performing electronic
literature searches in food and feed safety’ when performing the searches and documenting its
outcome. Moreover, applicants are encouraged to refer to Appendix D of the ‘Tools for critically appra
ising different study designs, systematic review and literature searches’ for assessing the quality of the
search.
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The search methodology must be documented and reported in detail to ensure transparency and
enable the evaluation and replication of the strategy. The following must be reported:
For database searches:
– the name of the database and the service provider used;
– the date of the search and the date range searched;
– any limits placed on the search such as language or publication status;
– the full search strategy (all terms and set combinations) and the number of records retrieved.
For sources other than bibliographic databases:
1) Websites and journal table of contents
– the name of the resource (i.e. website name, the journal name in case of searching in speciﬁc
tables of contents);
– the URL (uniform resource locator, the internet address);
– the date on which the search was conducted and the date range of the search, or the dates,
volumes and issues in the case of table of contents;
– the method of searching, e.g. browsing, using the search engine or scanning tables;
– any limits applied to the search (e.g. publication types);
– the search terms used and the number of relevant summary records or full-text documents
retrieved.
2) References lists
– the bibliographic details of the documents whose reference lists were scanned;
– the number of relevant bibliographic references retrieved.
The extensive literature search should cover at least the last 20 years. The list of relevant
references included should be compiled in a reference management software and provided in.RIS
format. Copies of the relevant papers should be provided. The applicant must ensure that terms and
conditions asserted by any copyright holder of publications or information submitted to EFSA are fully
satisﬁed. The applicant should consult with copyright licensing authorities (i.e. at national level) for
guidance on purchasing copyright licenses to reproduce any publications provided to EFSA. The
applicant remains solely responsible and liable for obtaining all necessary authorisations and rights to
use, reproduce and share the publications provided to EFSA.
If safety for one species/category is derived from literature studies and extrapolation to other
species/categories is required, the same principles as described under Section 5.7 should be followed.
4. Toxicity data from repeated dose studies in laboratory animals
For all additives with the exception of viable microorganisms, safety for target animals can be
derived from toxicological studies with oral administration in laboratory animals. These data should
allow establishing a lowest no observed adverse effect level (NOAEL) or a benchmark dose level
(BMDL) (e.g. BMDL5 for continuous data, BMDL10 for quantal data). Ideally, toxicological studies
should follow either the latest Organisation for Economic Cooperation and Development (OECD)
protocols or those in force at the time the study was made.
To derive a safe daily dose in the target species (mg/kg body weight (BW)), the NOAEL or BMDL,
expressed in mg/kg BW, is divided by an uncertainty factor of 100 (to cover intra- and interspecies
variation).4 The maximum safe concentration in feed (mg/kg complete feed, ‘as is basis’) is obtained
by dividing this safe daily dose by the default feed intake (FI; expressed as a g DM per kg BW,
Table 1). The resulting value (mg additive/g DM feed) is multiplied by 1,000 to express the feed
concentration per kg complete feed and multiplied by 0.88 (or 0.945 for milk replacer for veal calves)
to transform it to as is basis (assuming 88% DM for complete feed and 94.5% for milk replacers).
Maximum safe concentration in feed = ((NOAEL/100)/FI) 9 1,000 9 0.88
4 The uncertainty factor may be adjusted to take into account particular metabolic considerations, the nature and quality of the
toxicological studies, etc.
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The default values of feed intake in Table 1 are derived from estimated values of body weight and
derived feed intake of the animals at the end of a tolerance study. For animals not listed in Table 1,
the applicant should propose the default values.
For additives intended to be used in water, safe concentrations in water can be derived from the
safe concentrations in feed (see Section 2.5.1 of the Guidance on the identity, characterisation and
conditions of use of feed additives).
If speciﬁc toxicological data are not available, the thresholds of toxicological concern (TTC)5 could
be applied to ﬂavouring additives only for which a Cramer structural class can be assigned. Assignation
to a Cramer class is made using the OECD toolbox6 or other commercial software. The ‘maximum
acceptable feed concentrations’ are derived from the thresholds of the TTC approach and based on the
default values of feed intake shown in Table 1. Substances in Cramer class I would result in a
maximum acceptable concentration in complete feed (mg/kg feed) between 0.3 and 1.5, for Cramer
class II between 0.1 and 0.5 and for Cramer class III between 0.02 and 0.08.
5. Tolerance studies in target animals
If safety for the target species cannot be established at the maximum proposed concentration by
the methods described above, then in vivo studies in the relevant target species/categories are
required. The number of tolerance studies required in different animal species/categories is described
in Section 5.7.
The aim of the tolerance study is to provide a limited evaluation of short-term toxicity and a margin
of safety7 of the additive to the target animals. It is recommended to combine the tolerance study
with one of the efﬁcacy trials, whenever possible. If this is done, then all experimental groups should
be included in the statistical analysis.
Studies should be performed and documented according to appropriate quality standards and
should respect the rules on animal welfare laid down by EU legislation, particularly those listed in
Directive 63/2010/EU. Trials should be compliant with the criteria established by a recognised,
Table 1: Default values for daily feed intake scaled to body weight (g dry matter (DM)/kg body
weight) for the main animal species/categories
Animal category
Default values daily
feed intake (g DM/kg
body weight)
Values derived from
Body
weight (kg)
Feed intake
(kg DM/day)
Chicken for fattening 79 2 0.158
Laying hen 53 2 0.106
Turkey for fattening 59 3 0.176
Piglet 44 20 0.88
Pig for fattening 37 60 2.20
Sow lactating 30 175 5.28
Veal calf (milk replacer) 19 100 1.89
Cattle for fattening 20 400 8.0
Dairy cow 31 650 20.0
Sheep/goat 20 60 1.2
Horse 20 400 8.0
Rabbit 50 2 0.1
Salmon 18 0.12 0.0021
Dog 17 15 0.250
Cat 20 3 0.060
Ornamental ﬁsh 5 0.012 0.000054
DM: dry matter.
5 JECFA (FAO/WHO, 1996, Food additive series 35, IPCS, WHO Geneva). Review of the Threshold of Toxicological Concern (TTC)
approach and development of new TTC decision tree. EFSA supporting publication 2016: EN-1006. 50 pp. http://onlinelibrary.
wiley.com/doi/10.2903/sp.efsa.2016.EN-1006/pdf
6 http://www.oecd.org/chemicalsafety/risk-assessment/theoecdqsartoolbox.htm
7 Margin of safety: ratio of the highest tolerated additive concentration in feed and the highest use level proposed.
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externally audited, quality assurance scheme (e.g. good laboratory practice (GLP) in accordance with
Directive 2004/10/EC). Evidence should be provided that the work was done by qualiﬁed personnel
using appropriate facilities and equipment and responsible to a named study director. Studies
conducted outside the European Union must follow the same quality standards.
5.1. Test item
Tolerance studies should be based on the additive(s) for which application is made, except in
cases where a concentrated form of the additive(s) is recommended for testing (e.g. enzymes and
microorganisms). Any other deviations because of practical or other considerations should be
justiﬁed. A certiﬁcate of analysis of the test item used in the study should be provided. The additive
could be administered via feed or water for drinking depending on the conditions of use. The
concentration of the active substance(s) or agent(s) in the feedingstuffs/water should be conﬁrmed
by analysis.
5.2. Experimental groups
The design of a tolerance test includes a minimum of three groups:
– a control group
The diet/water of the control group should normally not contain the additive tested.8 However,
in case of additives for which a nutritional requirement exists, the control group should receive
the additive at the lowest requirement level (e.g. according to the National Research Council
(NRC), Gesellschaft f€ur Ern€ahrungsphysiologie (GfE) or other national data).
– a use-level group
The diet/water of the use-level group should normally contain the additive at the highest
recommended concentration. For those additives for which a maximum concentration is not
recommended, the highest typical use level should be used.
– an overdose group with a multifold of the use-level.
When the multifold concentration tested is:
– ≥ 100, test animals should be routinely monitored for visual evidence of clinical signs,
performance characteristics and product quality where relevant.
– 10 to < 100: in addition to the above, haematology and blood chemistry as described in
Section 5.5 and other parameters likely to be related to the biological properties of the additive.
– ≤ 10: in addition to the above, gross pathology and histopathology if relevant, as described in
Section 5.5. The study should be designed in such a way that a margin of safety for the
additive can be estimated. It is recognised that in some cases, ethical and practical
considerations will prevent performing necropsy in certain species/categories (e.g. pets, dairy
cows, sows, horses).
Where relevant, higher concentration of the active substance or agent can be obtained by omitting
or reducing the amount of carrier. For fermentation products, the ratio of active agent(s)/substance(s)
to the other fermentation products must remain the same as in the additive.
The setting conditions (e.g. temperature, light exposure) should be the same for the various groups
including housing, husbandry and diet/water administration.
5.3. Animals
Animals used should be healthy and preferably from a homogeneous group. Housing and
husbandry conditions should be adequate for the purpose of the study and conform to animal welfare
regulations. Preventive treatments with antibiotics/antimicrobials before the start of the trial should be
avoided. The acceptability of trials in which animals are treated with antibiotics/antimicrobials during
the course of the study will depend on a variety of factors, including the number of animals treated,
duration of the treatment, distribution between experimental groups and severity of the disease. The
8 When the additive modiﬁes the physicochemical properties of the feed, this should be considered in formulating the feed for a
control group.
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acceptability of these studies will be assessed on a case-by-case basis. Any therapeutic/preventive
treatments should not interact with the proposed mode of action of the additive and should be
recorded individually. Studies with an abnormally high mortality in the control group will not be
accepted. This would be judged against European industry standards.
For food-producing animals, the conditions of the study should be such that optimal performance
as described for the breed (e.g. performance standards of breeder companies) could be reached. The
higher the zootechnical performance of the animals in a given physiological stage, the more sensitive
the endpoint(s) would be to adverse situations. Therefore, it is recommended to use in studies with:
– chickens for fattening: only male birds
– laying hens: birds in the ﬁrst third of the laying period
– dairy cows: high-yielding animals in the ﬁrst third of the lactation period
– growing pigs: weaned piglets of both sexes
– cattle: weaned male bovines at the beginning of the fattening period
– salmonids: juvenile phase.
These recommendations are indicative of the most sensitive conditions for the assessment of safety
for the target animals. The applicant may deviate from these recommendations provided that
adequate justiﬁcations are submitted. The use of both sexes implies separate penning and statistical
evaluation (with the exception of piglets).
The recommended age/weight for the different species/categories at the start of the study is
detailed in Section 5.6.
5.4. Statistical considerations
5.4.1. Design of the experiment
The experimental unit is the smallest entity to which a given treatment is applied. If animals are
penned in groups and all the animals in the pen share the same feed source (and feed intake is not
measured individually), then the experimental unit for all parameters is the pen, not the individual
animal.
Experimental units allocated to the various experimental groups should not differ in a systematic
way. Therefore, a recognised method of randomisation should be used to allocate treatments to the
experimental unit (e.g. pen, animal). A randomised block design should be preferably used to control
for experimental settings like location within facilities. The same design is also recommended in case of
large experiments to ensure concurrency in measurements/determination of endpoints across
treatments. Other designs might be also appropriate, in which case the applicant should justify the
rationale for the design chosen.
In case of a signiﬁcant variability across animals of factors which could inﬂuence the outcome of
the study, animals should be stratiﬁed before being randomly allocated to pens/cages/treatments.
These factors might include initial body weight, age, stage of lactation, milk yield, parity and egg
production.
A proper method for randomisation should be used in order to allow allocation concealment (no
a priori knowledge of group assignment). In practice, the randomisation process must ensure that
investigator cannot inﬂuence the allocation of units to the various groups. It is recommended to
implement blinding of the caregivers and investigators, where possible, for instance using a proper
codiﬁcation of the treatment to be administered.
5.4.2. Sample size
Statistical considerations should be used to determine the size of the sample used to evaluate the
potential safety concerns. The setting of the null and alternative hypotheses should be done in light of
the problem formulation. Tests for equivalence or non-inferiority should be done for experiments
aiming at demonstrating similarity or non-inferiority between treated groups and control. Difference
testing should be used when the purpose is to conﬁrm superiority or inferiority (i.e. alternative
hypothesis stating a difference exists). For difference testing, when only one direction of the effect is
biologically relevant, a one-sided test should be used. A two-sided test is recommended in all other
cases. For the key endpoints, considerations for sample size calculation need to include: (i) the
magnitude of the effect that the study is designed to test and its variability; (ii) the expected direction
of the effect; (iii) an adequate statistical power and (iv) the conﬁdence level. The magnitude of the
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effect considered biologically relevant (for difference testing) or the similarity/non-inferiority range (for
equivalence/non-inferiority testing) should be clearly indicated for each endpoint. Key endpoints
include feed intake for all animals and, depending on the production stage, at least one additional
endpoint (e.g. body weight gain, egg or milk production, reproductive performance) should be
considered. It should be noted that additional key endpoints may arise from toxicological studies or
other parameters related to the biological properties of the additive. The highest sample size resulting
from the calculations for all key endpoints should be selected. The applicant should justify the
selection of the key endpoints.
The Type 2 (b) error measures the risk of non-detecting an effect (difference)/similarity
(equivalence) when it exists. As a guide, it should be lower than or equal to 20% in general, and 25%
for experiments with ruminants, minor species, pets and other non-food-producing animals. Hence, a
power (1-b) greater than or equal to 80% (75% for ruminants, minor species, pets and non-food-
producing animals) should always be ensured. Generally, a conﬁdence level of 95% is adopted when
testing difference, 90% for testing equivalence. Use of levels below these thresholds should be
justiﬁed.
5.4.3. Statistical analysis
The statistical analysis should be performed using models that allow comparing treated and control
groups whilst controlling for factors that could inﬂuence the outcome of the experiment whenever
possible. The class of generalised linear mixed models (McCullagh and Nelder, 1989), known as GLMM,
offers a suite of methods ﬂexible enough to ﬁt most of the experimental settings. Typically, this type of
models includes the treatment and other stratiﬁcation variables (e.g. age) as ﬁxed factor and blocking
factors, if any, as random (e.g. animal/pen location) or as covariates. The response variable is the
endpoint under investigation. Under certain conditions, a log or other transformations can be needed
in order to linearise the relationship with the explanatory factors. Depending on the type of response
variable (i.e. continuous, quantal, binary), different kinds of statistical tests and distributional
assumptions could be required. The applicant is requested to assess which one is more appropriate
and to provide the rationale of the choice. An indicator of quality of ﬁt should always be provided.
The analysis of variance is one of the simplest models included in the GLMM class. When using this
method, a test for group differences should be carried out preferably using the Scheffe, Dunnet, Tukey
(Sachs and Hedderich, 2006) or other comparable tests any time multiple comparisons are performed
concurrently. Non-parametric tests may be necessary if only a low number of observations is available,
but applicants are encouraged to use sufﬁcient replicates to allow for parametric tests to be
performed. When different additives are assessed concurrently using the same control, the statistical
evaluation should be done considering only the control and the groups treated with the additive under
assessment.
5.5. Endpoints
The endpoints to be measured depend on the design of the tolerance study (see Section 5.2). The
minimum required parameters for the different groups of endpoints are listed below and may be
augmented on a case-by-case basis.
5.5.1. Performance parameters and related parameters
Feed intake, initial and ﬁnal body weight, body weight gain, feed to gain ratio, water intake for
those additives administered via water. Clinical observations (by a veterinarian or under veterinary
supervision) including general health status, behaviour, morbidity and mortality (including culling).
In addition,
– for laying hens: laying rate, egg weight, shell quality, feed to egg mass ratio, egg mass/hen per
day
– for breeding hens: additionally to those required for laying hens, fertility, hatchability and chick
viability
– for dairy animals: milk production (also fat corrected milk), milk composition (total solids,
protein, fat, lactose and urea), somatic cell counts, protein, fat and lactose yield
– for sows: number of piglets born, piglets born alive, litter weight at birth and at weaning,
number of piglets weaned, weaning to oestrus interval
– for ﬁsh: speciﬁc growth rate (preferably thermal growth coefﬁcient (Jobling, 2003)).
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5.5.2. Haematology and clinical chemistry
Generally, samples for haematology and blood chemistry analysis should be taken at the end of the
study. Samples should be taken at the start of the trial to establish a baseline in studies involving
cattle for fattening, dairy cows, sows, horses, dogs and cats. Samples should be taken from all
experimental units and ideally from all animals. However, when total numbers of animals makes it
impractical, subsets of animals/pen should be identiﬁed for sampling by a random process carried out
at the beginning of the study. As a guide, the subset should represent at least 10% of the animals/
pen, but in no case less than two animals/pen. Blood samples should not be pooled.
The parameters to be measured should at least include (as appropriate):
Total count for red blood cells, packed cell volume, haemoglobin, mean corpuscular volume, mean
corpuscular haemoglobin, mean corpuscular haemoglobin concentration, total and differential counts
for leukocytes, platelet counts, prothrombin time and ﬁbrinogen (with the exception of the latter two
parameters for ﬁsh).
Sodium, potassium, chloride, calcium, phosphate, magnesium, total protein, albumin, globulin,
glucose, urea/uric acid (non-protein nitrogen for ﬁsh), cholesterol, creatinine, bilirubin, acute phase
proteins, amylase, alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase,
gamma-glutamyltransferase, alkaline phosphatase and creatine kinase.
Where available, scientiﬁc studies reporting reference ranges for the haematology and blood
chemistry parameters should be submitted for the species of the tolerance study.
5.5.3. Tissues/organs from necropsy
The following organs and tissues (as appropriate) from all groups should be examined grossly
(including weight of the organs) and preserved for microscopic evaluation: liver, kidneys, spleen,
adrenal gland, lung, stomach, pancreas, small intestine, colon, caecum, thymus, thyroid gland, heart,
intestinal lymph nodes, ovaries/testes. For ﬁsh, the following organs should be investigated, kidney,
liver, spleen, stomach (where present) and intestinal tract, heart, gonads, gills, bone and eye.
Histopathology is normally required only when indicated by ﬁndings in the gross pathology.
In all cases, critical endpoints known from the toxicological studies in laboratory animals should be
considered. Any adverse effect detected during efﬁcacy trials should also be reported in this section.
All deaths should be explained and, if necessary, investigated by gross pathology and histopathology.
5.6. Duration of the tolerance study
The necessary minimum duration of tolerance trials depends on the animal species/category and is
reported in Table 2.
Table 2: Minimum duration of tolerance studies for the main animal species/categories
Category
Deﬁnition of the animal
category
Start, from Duration
Piglets Young animals having completed
the suckling period
Weaning (or not more than
7 days after weaning)
42 days
35 days if growth rate
is ≥ 0.5 kg/day
Pigs for fattening Animals intended for meat
production until day of transport to
slaughterhouse
20–35 kg 42 days
Sows Female animals having been
inseminated/mated
From insemination/mating One cycle: from
insemination to the
ﬁrst oestrus after
weaning
Chickens for fattening Birds raised for fattening Hatch 35 days
Laying hens Productive female birds held for
egg production purposes
From 20 weeks of age 56 days
Breeder hens Female birds held for breeding
purposes
From 25 weeks of age 56 days
Turkeys for fattening Birds raised for fattening Hatch 42 days
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Tolerance studies for pigs for fattening are not needed if safety for weaned piglets is established.
Tolerance studies for chickens for fattening/reared for laying and turkeys for fattening should
normally be performed with 1-day-old birds. Tolerance data from chickens or turkeys for fattening are
generally taken to include chickens reared for laying or turkeys reared for breeding, respectively.
If calves for rearing and cattle for fattening were applied for, a combined study (28 days for each
period) would be considered sufﬁcient.
For minor species not included in the tables above, the duration of the studies should correspond
to that of the physiologically related major species listed in Table 3. For all other species, the minimum
duration should be 42 days for growing animals and 56 days for adult animals.
If an additive is applied for a speciﬁc and shorter period than that given in the tables above, it
should be administered according to the proposed conditions of use. However, the observation period
should not be shorter than 28 days and should involve the relevant endpoints (e.g. for sows for
reproduction the number of piglets born alive when considering the gestation period, or the number
and weight of weaned piglets when considering the lactation period).
5.7. Requirement for tolerance studies
In principle, tolerance tests should provide evidence of the safety of the additive for each of the
target species/animal categories for which an application is made. If the application covers only one
animal category (as deﬁned in Annex IV of Regulation (EC) No 429/2008), at least one study in this
category is required.
When the application covers several target species/categories, it is recognised that it may be
unrealistic to expect studies in all potential target species for which application is made, especially
when the application is for all animal species. Therefore, interspecies extrapolation of data can be
applied. In principle, data can be extrapolated between physiologically similar species (Table 3). The
degree to which species are physiologically related is judged predominantly in terms of gastrointestinal
Category
Deﬁnition of the animal
category
Start, from Duration
Turkeys for breeding
purposes
Female and male birds held for
breeding purposes
From 32 weeks of age 56 days
Calves Calves which are reared for
reproduction, veal production or
beef production
1 week of age (for veal
production, from 1 to
3 weeks of age)
42 days
Cattle Bovine animals that have
completed the weaning period
Full development of
rumination but < 6 months
of age
42 days
Cows Lactating cows 4 weeks after beginning of
lactation
56 days
Lambs/kids Young animals reared for
reproduction or meat production
1–4 weeks of age 42 days
Sheep/goats Lactating animals 4 weeks after beginning of
lactation
56 days
Salmon and trout Growing salmonids Trout: 10
Trout: 10 g
Salmon: 50 g
90 days
Other ﬁn ﬁsh Growing ﬁn ﬁsh 90 days
Crustaceans Growing crustaceans 90 days
Rabbits Rabbits that are reared for
reproduction or meat production
Beginning 1 week after
birth
42 days
Breeding does Does that have become pregnant
at least once
From insemination to
the end of weaning
period (one cycle)
Cats 28 days
Dogs 28 days
Other non-food-
producing animals
28 days
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function. Similarities in metabolism are also considered. In general, the extrapolation is limited
between animals which are kept for the same purpose, i.e. meat production or reproduction (including
milk or egg production).
Data from tolerance studies in the individual species/categories listed in column 1 of Table 3 can
be used to support the safety for other physiologically related species/categories, provided a sufﬁcient
margin of safety (the ratio of tolerated to maximum proposed use level)9 is established for the
species/category used for the extrapolation. If the margin of safety is not sufﬁcient, then speciﬁc
tolerance studies in the relevant species/categories should be provided.
– If the application is for all poultry/avian species, then tolerance studies should be provided with
chickens for fattening and laying hens. In order to cover species for breeding, an additional
limited study in breeding hens considering only performance endpoints (see Section 5.5) should
be submitted.
– If the application is for all Suidae, then tolerance studies should be submitted for weaned
piglets and sows.
– If the application is for all ruminant species, then tolerance studies should be submitted in
cattle for fattening and dairy cows.
– If the application is for all ﬁsh, then tolerance studies should be submitted in a salmonid
(salmon or trout) and another species (e.g. carp, sea bream, sea bass). If the application
includes crustaceans, then an additional study in shrimp would be required.
Extrapolation of the conclusions of tolerance studies can also be done to non-physiologically similar
species provided studies are done with a set of different species and a sufﬁcient margin of safety can be
established in all the species tested. If the margin of safety is not sufﬁcient in all the different species, a
limited extrapolation to other species may still be possible, but limited between the species/categories
listed in Table 3, as described above.
– If the application covers two food-producing animal species (e.g. pigs and poultry), then the
requirement would be limited to a total of three tolerance studies including both species and
covering growing and reproductive animals. The recommendations for the use of certain animal
categories in tolerance studies (Section 5.3) should be taken into consideration.
– If the application is for all pets and non-food-producing animals, tolerance studies would be
required for cats, dogs and a third species (e.g. a laboratory animal).
– If the application is for horses, it may be possible to derive tolerance from studies with cattle
(cattle for fattening or dairy cows) and pigs (pigs for fattening or sows).
– If the application is for all terrestrial animal species, tolerance studies should be provided with
at least chickens for fattening, piglets and dairy cows.
– If the application is for all animal species, tolerance studies should be provided in at least
salmonids, chickens for fattening, piglets and dairy cows.
Table 3: Extrapolation of tolerance data from certain species to other physiologically related species
From To physiologically related species
Chickens for
fattening
Other poultry for fattening (e.g. turkeys, ducks, goose, pheasants, quail, guinea fowl, ostrich)
and ornamental birds
Laying hens Other birds kept for egg production* (e.g. ducks, goose, pheasants, quail, guinea fowl,
ostrich)
Pigs Other Suidae
Calves or cattle Other growing ruminants (e.g. sheep, goat, buffalo) at the corresponding developmental stage
Dairy cows Other dairy ruminants (e.g. goat, sheep, buffalo)
Salmon or trout Ornamental ﬁsh
*: Extrapolation to breeders (including turkeys) is only possible if additional data on breeding endpoints are available.
9 A sufﬁcient margin of safety generally is at least 10, meaning that a concentration of at least 10 times the highest
recommended (approved) concentration of the additive was tolerated by relevant species without any adverse effects.
However, for some substances (e.g. organic acids, some ﬂavourings, some clays, some coccidiostats), a lower margin of safety
may be considered.
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For certain types of additives, the requirements for tolerance studies above may be modiﬁed:
– For nutritional additives where a tolerance study is required, target animal safety data can be
derived from one study in a target species or laboratory animal.
– For silage additives for which tolerance studies are required, it is usually sufﬁcient to restrict
tolerance to a ruminant species, normally the dairy cow. Studies involving other species are
required only when the nature of the ensiled material makes it more appropriate for use with
non-ruminants or when there are particular concerns when treated silage is used for categories
other than adult ruminants (e.g. moist corn for pigs or ﬁsh silage for fur animals).
5.8. Reporting
For each tolerance study, a study report should be submitted describing the objectives, materials
and methods, results and conclusions. The initial protocol should be included; any deviations from the
protocol should be clearly indicated and justiﬁed in the ﬁnal report. The reports should include the
individual data in digital format and detailed results including descriptive statistics, statistical tests and
model outcomes. Reports should start with a trial protocol data sheet (Appendix A) followed by the full
study report. International units should be used to express the results.
It is recommended that the study report follows the structure detailed below and contains the
following information. Applicants are encouraged to follow the recommendations of the EFSA guidance
on statistical reporting.
Title: The title should provide a concise and clear description of the study, including the type of
study, the product under assessment and animal species/category.
Summary: The summary should include the objectives, a description of the design and methods,
the main results and the conclusions of the study.
Objectives: The objectives of the study should be clearly described.
Materials and methods: Methods, apparatus and materials used, details of the species, breed or
strain of the animals, their number and the conditions under which they were housed and fed. In
particular, the following should be recorded and reported:
Ethical statement
1) Indicate compliance with national or institutional guidelines for the care and use of animals.
Animals, housing and husbandry
2) Animals: species (for aquatic species intended for human consumption: identiﬁcation should
be made by their colloquial name followed in parenthesis by the Latin binomial), breed, age
(and size/length for aquatic species), initial body weight, sex, identiﬁcation procedure,
physiological stage and general health.
3) Husbandry conditions: feeding and rearing conditions (pen/tank size, stocking density,
temperature, lighting); for aquatic species water quality including water ﬂow rate, water
temperature and salinity, where relevant.
4) Diets: description of manufacture, form and quantitative composition of the diet(s) in terms
of ingredients used, relevant nutrients (calculated and analysed values) and energy
(digestible, metabolisable or net).
Study design
5) Study location, dates and responsible individuals.
6) Study duration.
7) The type of design of the study (e.g. factorial, stratiﬁed, crossover).
8) Experimental groups: number of treatment and control groups, numbers of replicates
(experimental unit) per group and number of animals per replicate.
9) The experimental unit (e.g. individual animal, pen) should be indicated.
10) The basis for the different measurements (e.g. individual animal, pen) should be indicated
for each parameter measured.
11) Rationale for the selection of the number of animals/replicates used (sample size
calculation). Power analysis should be provided.
12) Steps taken to minimise bias including randomisation and blinding (see Section 5.1.1 of the
EFSA guidance on statistical reporting (EFSA, 2014)).
Guidance on the safety for the target species
www.efsa.europa.eu/efsajournal 14 EFSA Journal 2017;15(10):5021
13) Test item: intended concentration of the active substance(s) or agent(s) in the
feedingstuffs.
Experimental procedures
14) The procedures carried out to the different experimental groups should be detailed. These
should include the parameters/endpoints measured, indicating when and how they were
measured and information on the methods of analysis.
15) The health of the animals should be monitored, morbidity and mortality (including culling)
recorded.
16) The methodology to correct feed to gain ratio for mortality (including culling) should be
reported.
Statistical methods
17) The result of the power analysis should be reported.
18) The methods to perform statistical analysis should be stated, including those used to
identify outliers and handle missing data. If any relevant data points are excluded from the
model (e.g. outliers), a justiﬁcation should be given.
19) Describe any methods used to assess whether the data met the assumptions of the
statistical approach.
Results: Results of the study should be presented for all endpoints considered in the study. Tables
should be used to summarise the results from treatments. For all endpoints which are measured on
individual animals in a pen, a summary parameter of the endpoint in the experimental unit should be
used (e.g. mean for continuous measurements such as body weight, median and counts for quantal
measurements such as severity of an outcome or mortality). Summary parameters should always be
adjusted for losses (mortality/culling). The distribution of losses within the treatment groups should be
assessed to avoid the risk of introducing a bias.
20) Health status of the animals, morbidity and mortality including culling. The timing and
prevalence of any unexpected/undesirable incident/effect in individuals or groups.
Therapeutic/preventive treatments, if any should be recorded. Likely cause of death should
be established by a veterinarian and reported.
21) The report should include data from all animals or experimental units involved in the trials.
Cases which cannot be assessed due to a lack or loss of data should be reported, and their
distribution within the groups of animals indicated.
22) Concentration of the active substance(s) or agent(s) in the feedingstuffs should be
periodically analysed and reported. A certiﬁcate of analysis of the test item used in the
study should be provided.
23) Report the results for each endpoint measured/analysis carried out, with a measure of
precision (e.g. standard error or conﬁdence interval).
24) The report should include descriptive statistics plus detailed outcome of any statistical
analysis performed for all measured endpoints and each time point.
25) The measurement units should be speciﬁed for any result reported.
Discussion
26) Interpretation of the results, taking into account the study objectives and hypotheses and
other relevant studies in the literature.
27) Comments on the study limitations including any potential sources of bias, any limitations
of the animal model and the imprecision associated with the results.
Conclusions
28) The conclusions from the study should be drawn considering the objectives of the study,
the hypothesis and the outcome of the study.
Individual data, certiﬁcates of analysis
29) The individual data should be provided in a form of an electronic database and should be
accompanied by a data dictionary containing the description of the variables and the
metadata needed to properly analyse them.
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30) All codes, log and complete outputs for the ﬁnal statistical analysis (i.e. the results and
analysis reported) should be provided in electronic format.
31) The report should include the certiﬁcates of analysis for the different analysis performed,
reports of the veterinary observations/gross pathology/histopathology, haematology/clinical
chemistry, etc.
6. Toxicological studies
The toxicological studies available for the active substance(s) should be taken into account when
assessing the safety for the target species.
Depending on structural alerts or other toxicological considerations, genotoxicity studies may be
required when the additive is intended for use in long living animals (e.g. pets) and reproduction
animals (e.g. cows, sows, breeder hens). This could be achieved by reference to published studies.
7. Interactions in vivo
Any known interactions of the additive with feed materials, other approved additives or medicinal
products should be documented.
For those additives which exert their activity mainly by binding (e.g. clays), there is the possibility
that the availability of crucial nutrients, micronutrients and other additives could also be affected. It is
recognised that it is not practical to consider all possible nutrients/additives. Therefore, it is
recommended to measure apparent digestibility of crude protein, zinc, retinyl or tocopheryl esters,
thiamin or pyridoxine and an ionophore coccidiostat; the latter in the case, the additive is intended to
be used in poultry/rabbits. Such studies should be performed with the highest recommended
concentration of the additive and could be made in the context of a tolerance/efﬁcacy study. For other
additives which may have a negative impact on the absorption of nutrients, a similar approach should
be taken.
8. Microbial studies
Studies are only required when:
• the tolerance test give an indication of an adverse effect related to digestive tract
disturbances; or
• an adverse effect on the gut microbiota can otherwise be anticipated; or
• the additive shows speciﬁc antimicrobial activity at the feed concentration; or
• the additive is an ionophoric coccidiostat.
For the details on how to perform the studies, see the Guidance on the characterisation of
microorganisms used as feed additives or as production organisms.
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Appendix A – Trial Protocol data sheet
FOR TERRESTRIAL ANIMALS
Identiﬁcation of the additive: Batch number:
Trial ID: Location:
Start date and exact duration of the study:
Number of treatment groups (+ control(s)): Replicates per group:
Total number of animals: Animals per replicate:
Concentration(s) of the additive/active substance(s)/agent(s) (mg or Units of activity or CFU/kg complete feed or
L water)
Intended: Analysed:
†
Substances used for comparative purposes:
Intended concentration: Analysed:
Animal species/category:
Breed: Identiﬁcation procedure:
Sex: Age at start: Body weight at start:
Physiological stage: General health:
Additional information for ﬁeld trials:
Location and size of herd or ﬂock:
Feeding and rearing conditions:
Method of feeding:
Diets (type(s)):
Presentation of the diet: Mashh Pelleth Extrudedh Other
Composition (main feedingstuffs):
Nutrient content (relevant nutrients and energy content)
Intended values:
Analysed values:
Date and nature of the examinations performed:
Method(s) of statistical evaluation used:
Therapeutic/preventive treatments (reason, timing, kind, duration):
Timing and prevalence of any undesirable consequences of treatment:
Date Signature Study Director
†In case the concentration of the additive in complete feed/water may reﬂect insufﬁcient accuracy, the dose of the additive can
be given per animal/day or mg/kg body weight or as concentration in complementary feed.
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FOR AQUATIC ANIMALS
Identiﬁcation of the additive: Batch number:
Trial ID: Location:
Start date and exact duration of the study:
Number of treatment groups (+ control(s)): Replicates per group:
Total number of animals: Animals per replicate:
Concentration(s) of the additive/active substance(s)/agent(s) (mg, Units of activity, CFU/kg complete feed or L
water)
Intended: Analysed:
†
Substances used for comparative purposes:
Intended concentration: Analysed:
Route of administration:
Animal species/category:
Colloquial name: Latin binomial:
Breed: Identiﬁcation procedure:
Sex*: Age at start: Body weight at start:
Physiological stage: General health:
Fork length at start: Lighting conditions:
Water quality including temperature, salinity, O2 and CO2:
Additional information for ﬁeld trials:
Location, size and number of tanks or pens at the farm, production volume:
Feeding and rearing conditions:
Method of feeding:
Diets (type(s)):
Presentation of the diet: Mashh Pelleth Extrudedh Live feedh Other
Composition (main feedingstuffs):
Nutrient content (relevant nutrients and energy content of the feed)
Intended values:
Analysed values:
Date and nature of the examinations performed:
Response measures for efﬁcacy and tolerance:
Method(s) of statistical evaluation used:
Therapeutic/preventive treatments (reason, timing, kind, duration):
Timing and prevalence of any undesirable consequences of treatment:
Date Signature Study Director
†In case the concentration of the additive in complete feed/water may reﬂect insufﬁcient accuracy, the dose of the additive can
be given per animal/day or mg/kg body weight or as concentration in complementary feed.
*Where possible.
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